Investors can breathe easier with this top stock

Article Excerpt

ResMed specializes in products to treat sleep apnea and chronic obstructive pulmonary disease (COPD). However, with the onset of COVID-19, it is also accelerating production of its current lines of life support ventilators and non-invasive ventilators, as well as its ventilation mask systems. In fact, the company produced 52,000 non-invasive ventilators in the latest quarter, a three-fold increase over the normal quarterly rate. It also achieved a ten-fold increase in mask production in the quarter. While the sale of coronavirus-related products is a bonus for ResMed, its core business of CPAP masks for sleep apnea continues to lead the way—not just in terms of device sales, but also a continual stream of replacement parts. In addition, its devices wirelessly collect data from users about their machine use. That’s a new and exciting area for ResMed, and we think it will provide even more of a catalyst for strong investor returns. We still believe in RedMed’s prospects and its outlook. It’s a buy for Power Growth Investors. RESMED…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.